Growth hormone and prolactin responses to thyrotropin releasing hormone in patients with severe liver disease

A. E. Panerai, F. Salerno, M. Manneschi, D. Cocchi, E. E. Müller

Research output: Contribution to journalArticlepeer-review

Abstract

Thyrotropin-releasing hormone (TRH) was administered iv to 10 patients with severe liver disease and 10 control subjects. Injection of 400 μg TRH as a bolus induced in 7 out of 10 patients a clear-cut GH rise (≥10 ng/ml) occurring 15-120 min after the injection, and no effect on GH levels in controls. Mean baseline GH levels were higher in patients than in controls. An exaggerated and sustained PRL rise was present after TRH in the subjects with liver disease, whose mean baseline plasma PRL levels were within normal range.

Original languageEnglish
Pages (from-to)134-140
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume45
Issue number1
Publication statusPublished - 1977

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Growth hormone and prolactin responses to thyrotropin releasing hormone in patients with severe liver disease'. Together they form a unique fingerprint.

Cite this